Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections were first detected in Wuhan, China in December 2019 and resulted in a worldwide pandemic in 2020. SARS-CoV-2 infections totalled more than 180 million with 3.9 million deaths as of June 24, 2021. Tremendous research efforts hav...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2021
|
| Subjects: | |
| Online Access: | http://eprints.sunway.edu.my/2171/ http://eprints.sunway.edu.my/2171/1/landmark5024%20%289%29.pdf |
| _version_ | 1848802215792214016 |
|---|---|
| author | Lim, Hui Xuan * Masita, Arip Abdul Aziz, Al-Fattah Yahaya * Jazayeri, S. D. * Poppema, Sibrandes * Poh, Chit Laa * |
| author_facet | Lim, Hui Xuan * Masita, Arip Abdul Aziz, Al-Fattah Yahaya * Jazayeri, S. D. * Poppema, Sibrandes * Poh, Chit Laa * |
| author_sort | Lim, Hui Xuan * |
| building | SU Institutional Repository |
| collection | Online Access |
| description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections were first detected in Wuhan, China in December 2019 and resulted in a worldwide pandemic in 2020. SARS-CoV-2 infections totalled more than 180 million with 3.9 million deaths as of June 24, 2021. Tremendous research efforts have resulted in the development of at least 64 vaccine candidates that have reached Phase I to III clinical trials within 14 months. The primary efficacy endpoint for a random placebo-controlled clinical trial of a COVID-19 vaccine to be approved by US FDA should confer at least 50% protection against COVID-19. Three COVID-19 vaccines (BNT162b2, mRNA-1273 and Sputnik V) in clinical Phase III trials have now achieved >90% efficacy in preventing COVID-19. Since SARSCoV-2 is highly contagious, vaccines are expected to achieve at least 80% herd immunity in the world’s population to effectively prevent SARS-CoV-2 infections. An overview of safety, immunogenicity and efficacy of the current frontrunner vaccines are reviewed. |
| first_indexed | 2025-11-14T21:19:49Z |
| format | Article |
| id | sunway-2171 |
| institution | Sunway University |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-14T21:19:49Z |
| publishDate | 2021 |
| publisher | IMR Press |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | sunway-21712023-04-06T09:41:15Z http://eprints.sunway.edu.my/2171/ Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials Lim, Hui Xuan * Masita, Arip Abdul Aziz, Al-Fattah Yahaya * Jazayeri, S. D. * Poppema, Sibrandes * Poh, Chit Laa * RA Public aspects of medicine Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections were first detected in Wuhan, China in December 2019 and resulted in a worldwide pandemic in 2020. SARS-CoV-2 infections totalled more than 180 million with 3.9 million deaths as of June 24, 2021. Tremendous research efforts have resulted in the development of at least 64 vaccine candidates that have reached Phase I to III clinical trials within 14 months. The primary efficacy endpoint for a random placebo-controlled clinical trial of a COVID-19 vaccine to be approved by US FDA should confer at least 50% protection against COVID-19. Three COVID-19 vaccines (BNT162b2, mRNA-1273 and Sputnik V) in clinical Phase III trials have now achieved >90% efficacy in preventing COVID-19. Since SARSCoV-2 is highly contagious, vaccines are expected to achieve at least 80% herd immunity in the world’s population to effectively prevent SARS-CoV-2 infections. An overview of safety, immunogenicity and efficacy of the current frontrunner vaccines are reviewed. IMR Press 2021-11-30 Article PeerReviewed text en cc_by_4 http://eprints.sunway.edu.my/2171/1/landmark5024%20%289%29.pdf Lim, Hui Xuan * and Masita, Arip and Abdul Aziz, Al-Fattah Yahaya * and Jazayeri, S. D. * and Poppema, Sibrandes * and Poh, Chit Laa * (2021) Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials. Frontiers in Bioscience-Landmark, 26 (11). pp. 1286-1304. ISSN 2768-6698 https://doi.org/10.52586/5024 10.52586/5024 |
| spellingShingle | RA Public aspects of medicine Lim, Hui Xuan * Masita, Arip Abdul Aziz, Al-Fattah Yahaya * Jazayeri, S. D. * Poppema, Sibrandes * Poh, Chit Laa * Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials |
| title | Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials |
| title_full | Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials |
| title_fullStr | Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials |
| title_full_unstemmed | Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials |
| title_short | Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials |
| title_sort | immunogenicity and safety of sars-cov-2 vaccines in clinical trials |
| topic | RA Public aspects of medicine |
| url | http://eprints.sunway.edu.my/2171/ http://eprints.sunway.edu.my/2171/ http://eprints.sunway.edu.my/2171/ http://eprints.sunway.edu.my/2171/1/landmark5024%20%289%29.pdf |